Le Lézard
Classified in: Science and technology
Subjects: PDT, MAT

New Online Service Gives Canadians Better Access to Medical Cannabis


Physician-led Cannalogue offers patients choice and convenience through online marketplace

TORONTO, March 11, 2020 /CNW/ - Built by doctors. Made for patients.  That's the philosophy behind a new online service for Canadians in search of enhanced access to medical cannabis.  As the first direct-to-sales provider licensed by Health Canada, Cannalogue is an easy-to-use online marketplace for medical cannabis products.

With Cannalogue, Canadians will no longer need to guess which medical cannabis products or dosages are best for their health conditions.  In conjunction with affiliate clinic Oridon Medical, Cannalogue provides a free medical assessment, personalized treatment plan, and the ability to fill prescriptions for medical cannabis, all from the comforts of home. 

"We know how difficult it can be for patients to access physicians and healthcare practitioners specialized in prescribing medical cannabis and Cannalogue is here to help," says President and CEO, Dr. Mohan Cooray.  "Contrary to products currently available to consumers at the recreational level, our medical staff attend to the needs of patients to determine the best treatment plan possible. Our clinically-focused approach gives patients better control over their health and long-term symptoms," he says.

Cannalogue's Amazon-like service offers patients a choice of physician-recommended medical cannabis products which eliminates the need for repetitive visits to the doctor for modifications to prescriptions. "Patients are no longer confined to a one prescription - one licensed producer system.  Patients have choice with Cannalogue," says Dr. Cooray.  "Our products have been carefully selected by physicians based on quality and effectiveness, so patients can simply log in to Cannalogue.ca and choose from a range of licensed producers without the hassle of additional doctor visits," he says.

For more information or to order medical cannabis online, visit www.cannalogue.ca.

Follow Cannalogue on Facebook | Twitter | LinkedIn | Instagram  

About Cannalogue:
Based in Toronto, Cannalogue is a rapidly emerging healthcare technology company that received Health Canada's first direct-to-sales licence for medical cannabis. Cannalogue's innovative technology provides a safe, controlled, and cost-effective online marketplace that is globally scalable into all medical cannabis markets.  Engineered by physicians Dr. Mohan Cooray and Dr. Andrew Lu, Cannalogue challenges the status quo and advocates on behalf of patients to educate medical professionals and government officials on the safety and benefits of medical cannabis as a viable treatment option to traditional therapies.

SOURCE Cannalogue


These press releases may also interest you

at 19:38
Illinois House Speaker Emanuel "Chris" Welch was unanimously recommended to serve as the new Proviso Township Committeeman in a meeting held Friday evening of the Executive Committee, replacing the late Karen Yarbrough....

at 19:08
Nium, the global leader in real-time, cross-border payments, and Asia's leading payments, banking, and capital markets research firm, Kapronasia, today launched "Breaking Borders: The Revolution of Real-Time Cross-Border B2B Payments in Asia" - a new...

at 18:13
In a digital era where the app market continues to expand, driven by increased smartphone adoption and technological advancements, Appsketiers emerges as a beacon of hope for aspiring entrepreneurs and innovators. With a mission to democratize app...

at 18:00
Voxtur Analytics Corp. , a North American technology company creating a more transparent and accessible real estate lending ecosystem, is pleased to announce that it has engaged the services of ICP Securities Inc. ("ICP") to provide automated market...

at 18:00
On April 19, 2024, the board of directors of Portland General Electric Company declared a quarterly common stock dividend of $0.50 per share, representing an increase of 5.3%, or $0.10 per share, on an annualized basis. The company's dividend is...

at 17:55
Oragenics, Inc. , a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") dated April...



News published on and distributed by: